
André Albergaria

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3503959/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	P-Cadherin Overexpression Is an Indicator of Clinical Outcome in Invasive Breast Carcinomas and Is Associated with CDH3 Promoter Hypomethylation. Clinical Cancer Research, 2005, 11, 5869-5877.	7.0	236
2	Monocarboxylate transporter 1 is upâ€regulated in basalâ€like breast carcinoma. Histopathology, 2010, 56, 860-867.	2.9	168
3	p63 expression in normal skin and usual cutaneous carcinomas. Journal of Cutaneous Pathology, 2002, 29, 517-523.	1.3	139
4	Epithelial E- and P-cadherins: Role and clinical significance in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 297-311.	7.4	137
5	Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Research, 2009, 11, R40.	5.0	134
6	Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. Oncogene, 2008, 27, 9-19.	5.9	130
7	Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells. Oncogene, 2010, 29, 392-402.	5.9	106
8	P-cadherin expression in breast cancer: a review. Breast Cancer Research, 2007, 9, 214.	5.0	93
9	The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. Molecular Cancer Therapeutics, 2007, 6, 3169-3179.	4.1	77
10	Pâ€cadherin functional role is dependent on Eâ€cadherin cellular context: a proof of concept using the breast cancer model. Journal of Pathology, 2013, 229, 705-718.	4.5	68
11	P-cadherin role in normal breast development and cancer. International Journal of Developmental Biology, 2011, 55, 811-822.	0.6	64
12	Pâ€Cadherin Is Coexpressed with CD44 and CD49f and Mediates Stem Cell Properties in Basalâ€like Breast Cancer. Stem Cells, 2012, 30, 854-864.	3.2	64
13	p40: A p63 Isoform Useful for Lung Cancer Diagnosis – A Review of the Physiological and Pathological Role of p63. Acta Cytologica, 2013, 57, 1-8.	1.3	52
14	Distribution of p63, a novel myoepithelial marker, in fine-needle aspiration biopsies of the breast. Cancer, 2003, 99, 172-179.	4.1	51
15	Nottingham Prognostic Index in Triple-Negative Breast Cancer: a reliable prognostic tool?. BMC Cancer, 2011, 11, 299.	2.6	50
16	P-cadherin signals through the laminin receptor α6β4 integrin to induce stem cell and invasive properties in basal-like breast cancer cells. Oncotarget, 2014, 5, 679-692.	1.8	49
17	P-cadherin, vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: an immunohistochemical study. Histology and Histopathology, 2010, 25, 963-74.	0.7	46
18	Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas. Breast, 2012, 21, 354-360.	2.2	43

#	Article	IF	CITATIONS
19	p63 staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast. Journal of Clinical Pathology, 2002, 55, 936-939.	2.0	38
20	Maspin expression in normal skin and usual cutaneous carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2002, 441, 551-558.	2.8	35
21	The basal epithelial marker P-cadherin associates with breast cancer cell populations harboring a glycolytic and acid-resistant phenotype. BMC Cancer, 2014, 14, 734.	2.6	25
22	P-Cadherin Expression in Canine Mammary Tissues. Journal of Comparative Pathology, 2004, 130, 13-20.	0.4	22
23	CCAAT/Enhancer Binding Protein β (C/EBPβ) Isoforms as Transcriptional Regulators of the Pro-Invasive CDH3/P-Cadherin Gene in Human Breast Cancer Cells. PLoS ONE, 2013, 8, e55749.	2.5	20
24	Naked nuclei revisited: p63 Immunoexpression. Diagnostic Cytopathology, 2002, 27, 135-138.	1.0	19
25	ICI 182,780 induces P-cadherin overexpression in breast cancer cells through chromatin remodelling at the promoter level: a role for C/EBPA in CDH3 gene activation. Human Molecular Genetics, 2010, 19, 2554-2566.	2.9	18
26	Estrogens, MSI and Lynch syndrome-associated tumors. Biochimica Et Biophysica Acta: Reviews on Cancer, 2009, 1796, 194-200.	7.4	14
27	Clinicopathological significance of ERCC1 expression in breast cancer. Pathology Research and Practice, 2013, 209, 331-336.	2.3	14
28	P-cadherin expression in glandular lesions of the uterine cervix detected by liquid-based cytology. Cytopathology, 2005, 16, 88-93.	0.7	11
29	Molecular phenotypes of matched in situ and invasive components of breast carcinomas. Human Pathology, 2011, 42, 1438-1446.	2.0	10
30	Homologous recombination deficiency as prognostic marker in metastatic gastric cancer Journal of Clinical Oncology, 2019, 37, 4040-4040.	1.6	2
31	Co-expression of E- and P-cadherin in breast cancer: role as an invasion suppressor or as an invasion promoter?. BMC Proceedings, 2010, 4, .	1.6	1